Characteristics and Rates of Diabetic Ketoacidosis (DKA) Among Users of Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors, Sitagliptin, or Short/Rapid-Acting Insulin: A Descriptive Analysis Read more about Characteristics and Rates of Diabetic Ketoacidosis (DKA) Among Users of Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors, Sitagliptin, or Short/Rapid-Acting Insulin: A Descriptive Analysis
Characteristics and Rates of Diabetic Ketoacidosis (DKA) by Chronic Kidney Disease (CKD) Stage Among Patients with Short/Rapid-Acting Insulin Use and Type 1 Diabetes Mellitus (T1DM): A Descriptive Analysis Read more about Characteristics and Rates of Diabetic Ketoacidosis (DKA) by Chronic Kidney Disease (CKD) Stage Among Patients with Short/Rapid-Acting Insulin Use and Type 1 Diabetes Mellitus (T1DM): A Descriptive Analysis
FDA Labeling Change: Additional Language to Mitigate the Risk of Hypoglycemia Associated with Beta Blockers in Children Read more about FDA Labeling Change: Additional Language to Mitigate the Risk of Hypoglycemia Associated with Beta Blockers in Children
Products for the Development of the Pregnancy Safety Study Framework & Use in Pregnancy Read more about Products for the Development of the Pregnancy Safety Study Framework